Agoracom Blog Home

Posts Tagged ‘Cannabis’

Medical Psilocybin and the Emerging “Functional” Mushrooms Market SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:08 PM on Wednesday, June 24th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

  • The remedial potential of psilocybin has helped open the doors to a new world of potential treatments and psychedelic therapies.

Psilocybin and a number of similar psychoactive compounds have begun to show potential as medical therapies. 

Psychedelic therapies including psilocybin, MDMA and other psychoactive compounds are slowly beginning to show medical potential as therapies designed to treat mental health concerns. Following the developmental model that saw cannabis rise from an illicit narcotic to a recognized form of medicine in a growing number of jurisdictions around the world, these psychedelic therapies may have the potential to provide significant medical benefits, especially for those suffering from mental health conditions such as post-traumatic stress disorder (PTSD), addiction issues or other ailments.

Psychedelic treatments, including psilocybin, gaining medical acceptance

In North America, a number of leading medical and academic institutions have already begun to explore the potential of psychedelic therapies. For example, in 2017 the US Food and Drug Administration (FDA) granted its “Breakthrough Therapy Designation” to MDMA for the treatment of PTSD. In 2019, 15 sites enrolled subjects in an FDA-regulated Phase 3 clinical trial of MDMA-assisted psychotherapy for PTSD.

According to MAPS, the FDA’s Breakthrough Therapy Designation is intended for drugs that may have the potential to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates the drugs could demonstrate substantial improvement over existing therapies. Like the US FDA, Health Canada has embraced the medical potential of psychedelic therapies. The Canadian regulatory authority has provided psychedelic therapy company Numinus (TSXV:NUMI) with an updated licence under the Controlled Drug and Substances Act to allow Numinus researchers to standardize the extraction of psilocybin from mushrooms.

Under the company’s existing licence, Numinus is authorized to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Moving forward, the company intends to pursue the potential benefits of psychedelic therapies through the research, development and distribution of these substances. “We are excited about the future of psychedelics, and our focus will solely be on its therapeutic use,” said Numinus CEO Payton Nyquvest. “Psychedelics will only move forward in a therapeutic and research context, where the application of these substances will only happen in safe, controlled treatment environments. Numinus has these pieces in place today.”

In order to bolster the company’s research and development plans, Numinus has signed a pair of medical experts in Dr. Evan Wood and Dr. Gabor Maté. Dr. Wood, a substance abuse expert with over 20 years of experience, is the Chief Medical Officer at Numinus, while Dr. Gabor Maté, a prominent physician and mental health advocate, is expected to inform the Numinus Clinical Advisory Council as a member. “Dr. Wood and Dr. Gabor Maté offer exceptional insights into the challenges of mental health and substance abuse, which complements our goals and mission at Numinus,” said Nyquvest.

Research and investment in psilocybin

The initial progress made in the world of psychedelic therapies has begun to reflect many of the early steps made by the cannabis industry on the path to acceptance. Across North America, the regulation of cannabis for strictly medical uses has often predated legal recreational use.

Recognizing the parallels in these emerging industries, a number of companies in the psychedelic therapy space are working with experts from the cannabis industry in order to educate the public and develop safe and consistent treatment options. There are many similarities between the medical cannabis market and the emerging medical psychedelic market; however, the nature of psychedelics involves a much more stringent set of regulations in order to ensure patients receive a treatment tailored to their unique condition. By working with regulators like Health Canada, companies such as Numinus have an opportunity to support the emerging field of psychedelic-assisted therapy and research by establishing safe and standardized dosages and delivery methods.

Future psychedelic therapy research

The challenging nature of mental health conditions such as PTSD, addiction, depression, anxiety and many others has caused neuroscientists to consider new therapies as well. In 2019 John Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research, a research facility focused on the study of compounds including LSD and psilocybin as a means of treating a variety of mental health concerns including anorexia, addiction and depression.

With US$17 million in funding, the center is working to move the field of psychedelic therapies forward while targeting a number of specific conditions. “It’s been hand-to-mouth in this field, and now we have the core funding and infrastructure to really advance psychedelic science in a way that hasn’t been done before,” said Roland Griffiths, the director of the center at Johns Hopkins. “The one that’s crying out to be done is for opiate-use disorder, and we also plan to look at that.”

Takeaway

Leading health authorities in both Canada and the United States have recognized the potential medical benefits of a number of psychedelic compounds. Through medical licensing agreements and research partnerships, both public and private institutions are slowly beginning to pinpoint the medical conditions that could most benefit from psychedelic therapies. As this research continues to improve our medical understanding of psychedelics, there is potential for new therapies to emerge with direct applications for a number of mental health concerns.

SOURCE: https://investingnews.com/innspired/medical-psilocybin-mushroom-market/

Mota Ventures and Sweet Earth Holdings Announce Exclusive Letter of Intent for the Sale of CBD Canine Products $SHRM $RVV $N $APH.ca $GBLX $PFE $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:28 AM on Monday, June 22nd, 2020

Vancouver, British Columbia–(Newsfile Corp. – June 22, 2020) – Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (“Sweet Earth“) and Mota Ventures Corp. (CSE: MOTA) (FSE: 1WZ1) (OTC Pink: PEMTF) (“Mota“) are pleased to announce that they have entered into a letter of intent (the “LOI“) under which Sweet Earth will become the exclusive dog treat provider to Mota’s eCommerce direct consumer brand, Nature’s Exclusive.

Sweet Earth is a complete vertically integrated “farm to shelf” company that is a member of the US Hemp Association and is Leaping Bunny Certified, while Mota is a direct to consumer provider of a wide range of CBD products in the United States and Europe. The two companies (the “Partners“) expect to sell Sweet Earth’s award-winning products, beginning with CBD dog treats and paw and nose balm, through Mota’s consumer brand, Nature’s Exclusive, which is sold in the United States. Mota has initially selected Sweet Earth’s popular Beef and Cheddar Potato CDB Dog Treats to be sold under the Nature’s Exclusive brand.

Figure 1: Sweet Earth’s Beef & Cheddar Potato CDB Dog Treats

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/3581/58280_08f27db6c4877b62_003full.jpg

Source: www.sweetearthcbd.com

Sweet Earth’s Dog Treats are Certified Organic and Leaping Bunny Certified1.

Each organic treat is fortified with Vitamin E as a natural preservative.

Packaging will be customized to the specifications of the Nature’s Exclusive brand.

According to Dogs Naturally2, research shows that CDB dog treats are effective dog supplements for:

  • Arthritis and joint pain
  • Anxiety
  • Digestive issues
  • Neurological disorders (such as seizures and epilepsy)
  • Blood disorders

According to Today’s Veterinary Business, the U.S. pet treat market reached US$6.7 billion in 2019, with CBD, the largest growth component3 within the pet treat sector. The journal’s research also provides insight into key trends in a sector that has continued to grow at an average 3% CAGR.

  • Online sales of pet snacks have rapidly grown from 0% to 13%. A catalyst of eCommerce’s rapid market expansion is attributed to the platform’s ability to educate consumers on products prior to purchase.
  • Dog owners are increasingly focused on quality snacks that are produced locally, as highlighted by the decrease in sales of import treats. Made in the USA4 has become a key factor in consumer purchasing.
  • 11% of dog owners have purchased dog supplements or treats containing CBD or hemp; however, as highlighted in Figure 2, the segment is far outpacing the overall growth of the pet snack and supplement sector.



Figure 2: Estimated Size and Growth of US CBD Pet Market

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/3581/58280_08f27db6c4877b62_004full.jpg

Brightfield Group5 estimates the US CDB pet market will increase from less than US$100 million in 2018 to approximately US$1.8 billion in 2023.

The 104% CAGR highlights a product with rapid expansion and penetration into the growing pet snack sector.

Global Market Insight predicts that the Dog Food and Snacks market will surpass US$75.0 billion by 2025 and increase to a CAGR of 4%

Hall of Fame Quarterback and Brand Ambassador to Sweet Earth, Warren Moon, commented, “I think the Partners will make a great team. Both come to the table with value-added capabilities and similar visions of providing high-quality products to discerning consumers.” Sweet Earth President, Amrik Virk commented, “this is a great opportunity for Sweet Earth to team with Mota, which has grown 110% YOY, and recently announced sales of C$5.1 million for the month of May.”

Readers are cautioned that the LOI does not set out the final terms for the collaboration between the Partners. The establishment of the sales partnership remains subject to the negotiation of definitive documentation between the Partners.

About Sweet Earth

Sweet Earth is a vertically integrated “farm to shelf” hemp grower with a farm in Applegate, Oregon, that maintains a full line of hemp and CBD products for the US and global market. Its products combine CBD with herbal and organic ingredients, all of which are selected for their beneficial properties to soothe, rejuvenate, and reduce inflammation. In addition to high-end finished products, Sweet Earth prides itself on sustainability by minimizing the use of plastics in both production and packaging.

Sweet Earth’s in-house genetics team has been working on its own proprietary hemp strain. This strain has been grown in its indoor greenhouse resulting in high yielding CBD rich flower. Sweet Earth looks forward to planting this new strain outdoors for the 2020 season. Sweet Earth products are sold on its website: www.sweetearthcbd.com.

About Mota Ventures Corp.

Mota Ventures is an established e-Commerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

On behalf of Mota Ventures Corp. 

Ryan Hoggan
Chief Executive Officer

For more information visit:
www.motaventuresco.com
or contact:

Joel Shacker
[email protected]
(604) 423-4733

On behalf of Sweet Earth Holdings Corp.

Amrik Virk
Director

For more information visit:
www.sweetearthcbd.com or contact:

Amrik Virk
[email protected]
(778) 385-1213

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Vertical Exploration $VERT.ca Retains WSP Canada Inc. To Assist With St-Onge Wollastonite Quarry Permitting Application $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 12:48 PM on Thursday, June 18th, 2020
  • Retained WSP Canada Inc. (WSP) to assist Vertical with its quarry permitting application.
  • Vertical’s operations partner, Magnor Exploration Inc., will work with WSP to support the preparation, drafting and submission of the full quarry permitting request

VANCOUVER, BC / ACCESSWIRE / June 18, 2020 / VERTICAL EXPLORATION INC. (TSX-V:VERT) (“Vertical”or “the Company”) is pleased to announce it has retained the services of WSP Canada Inc. (WSP) to assist Vertical with its quarry permitting application to the Government of Quebec for its St-Onge Wollastonite project located in the Lac-Saint-Jean region of Quebec.

Vertical’s operations partner, Magnor Exploration Inc., will work with WSP to support the preparation, drafting and submission of the full quarry permitting request, including an application under Section 22 of the Environmental Quality Act for a Certificate of Authorization (CA) from the Quebec Ministry of Environment and Fight against Climate Change (MELCC) as well as a request for a BEX (Bail d’Exploitation Miniere Permit) from the Quebec Ministry of Energy and Natural Resources (MERN).

WSP Canada Inc. is part of WSP Global Inc., which is one of the world’s leading professional services firms providing engineering and design services to clients in the transportation and infrastructure, property and buildings, environment, power and energy, resources, and industry sectors, as well as offering strategic advisory services. WSP Global Inc. has approximately 49,000 employees working in 500 offices across the globe.

Vertical is very pleased to have retained such a prominent professional services firm to support its quarry permitting application for St-Onge and looks forward to providing further updates on the permitting application in the near future.

Vertical advises that the production decision on the St-Onge deposit was not based on a feasibility study of mineral reserves, demonstrating economic and technical viability, and as a result, there may be an increased uncertainty of achieving any level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially minable deposit. Historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that production will occur as anticipated or that anticipated production costs will be achieved.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD

Peter P. Swistak, President/CEO

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

TransCanna $TCAN.ca Expands Distribution into the Los Angeles Market $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:53 AM on Wednesday, June 17th, 2020
tcan-square
  • Announce through its wholly-owned subsidiary Lyfted Farms Inc. an Inventory and Product Agreement with Cali Plug UHCC for its highly anticipated inaugural retail location
  • Cali Plug was founded in 2006 and is a significant influencer in the cannabis space, with approximately 200,000 Instagram followers (@caliplug)

Vancouver, British Columbia–(June 17, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce through its wholly-owned subsidiary Lyfted Farms Inc. (“Lyfted”) an Inventory and Product Agreement (the “Agreement”) with Cali Plug UHCC for its highly anticipated inaugural retail location. Cali Plug was founded in 2006 and is a significant influencer in the cannabis space, with approximately 200,000 Instagram followers (@caliplug).

July 2020 is the target date for the grand opening of this store. Through this Agreement, Lyfted Farms is expanding distribution into the greater Los Angeles area in collaboration with the brand new Cali Plug UHCC dispensaries www.calipluguhcc.com.

Cali Plug UHCC plans to feature the Lyfted Farms products in the new store and use their social media platforms to promote the Lyfted brand. Cali Plug has estimated foot traffic to exceed 1,000 customers daily for the downtown store. The first dispensary will be prominently located in downtown Los Angeles at 5925 South Alameda Street.

“Lyfted Farms is a powerhouse for premium indoor cultivation flower. Moving into the So-Cal market with Cali Plug flagship retail is going to be an incredible collaborative force,” states Cali Plug, Owner and Founder Michael Myers. “The flower is going to fly off the shelves. The So-Cal consumers demand the quality that Lyfted Farms can produce.”

Cannabis sales in California are expected to exceed U$5.1 billion for 2020, with more than half of that happening in the greater Los Angeles area. Southern California is the largest cannabis consumer market in the world.

“This Agreement helps us realize our broader strategy of aligning with authentic long-term California cannabis innovators while staying true to our end consumer,” said Bob Blink, Lyfted Farms Founder and TransCanna CEO. “We continue to build out the go-to-market strategy in anticipation of imminently receiving our Daly Building license.”

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Mota Ventures $MOTA.ca Appoints Roger C. Clinton as Member of Advisory Board to Verrian GmbH, Its Psilocybin Research Subsidiary $SHRM $RVV $N $APH.ca $GBLX $PFE $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 9:16 AM on Monday, June 15th, 2020

VANCOUVER, BC, CANADA / ACCESSWIRE / June 15, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH. Clinton is active within the addiction treatment and specifically opiate addiction research sector, seeking to bring attention to the issue and enhance promising treatment options using psychedelics in conjunction with behavioral therapy through his global network.

“I’m honored to be working with the team at Mota in a patient first approach. We believe the work that we’re doing can be transformative in people’s lives as they work daily to overcome addiction,” said Roger Clinton.

On June 2nd, Mota announced the $20,000,000 acquisition of Verrian, a European pharmaceutical manufacturer of natural psilocybin extracts. Verrian is focused on psychedelic and cannabis treatments of opiate addiction. Clinton will play a vital role in advising and enhancing the patient perspective as well as helping to shape R&D efforts of our world-renowned addiction medicine experts, resulting in best of breed psychedelic derived treatments for the global marketplace.

Ryan Hoggan, Chief Executive Officer, stated “We’re honored to be working with Roger, an advocate for patient first treatment options. Roger’s work in advocacy for opiate addiction research will enhance MOTA’s research efforts and help to draw attention to our ground-breaking psychedelic research we as we jointly seek new treatments to help patients overcome addiction.”

ABOUT ROGER

Roger Cassidy Clinton is a true multi-hyphenate: singer-songwriter, voice-over artist, actor, author, up-close political observer (quite the understatement) and, arguably, one of the world’s biggest sports enthusiasts. He is also a living, inspiring story of recovery.

Roger, President Bill Clinton’s younger brother, is blessed with a spectacular group of friends from all walks of life, including the “who’s who” in the world of music, entertainment, sports (collegiate and professional) and, of course, politics. Working, associating and performing with people who have attained the highest levels of success in their professions has enabled Roger to forge priceless relationships that will last a lifetime. These relationships have brought him many unique, exciting experiences with more than a few once-in-a-lifetime opportunities.

Throughout it all, however, Roger has struggled with decades of alcohol and substance abuse that at one point left him clinically dead. Miraculously, medical personnel were able to revive Roger, and he improbably averted tragedy and survived. Through his personal, ongoing journey of recovery from a life complicated by addiction and trauma, Roger is grateful to have gained profound insight that he is privileged to share in order to help spread light and optimism with the world.

This press release is available for investor discussion on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Psilocybin Seems to Turn Down the “Ego Center” in Brain SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:52 AM on Thursday, June 11th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

In a new study, Johns Hopkins Medicine researchers analyzed the brain scans of people after they took psilocybin, the active compound in psychedelic (magic) mushrooms, to see what happens in the brain when people are on psychedelics.

The team focused on a part of the brain known as the claustrum, taken from the Latin word for “hidden or shut away.” The claustrum is an extremely thin sheet of neurons deep within the cortex, yet it reaches out to every other region of the brain.

Its true purpose remains “hidden away” as well, with researchers speculating about its functions. For example, Dr. Francis Crick, the British biologist and neuroscientist who proposed the double helix structure of the DNA molecule, believed that the claustrum was the seat of consciousness, responsible for awareness and sense of self.

What is known is that this region contains a large number of receptors targeted by psychedelic drugs such as LSD or psilocybin.

To see what happens in the claustrum when people are on psychedelics, the researchers compared the brain scans of people after they took psilocybin with their scans after taking a placebo.

The scans after psilocybin use showed that the claustrum was less active, meaning the area of the brain believed responsible for setting attention and switching tasks is turned down when on the drug.

The researchers say that this ties in with what people report as typical effects of psychedelic drugs, including feelings of being connected to everything and reduced senses of self or ego.

“Our findings move us one step closer to understanding mechanisms underlying how psilocybin works in the brain,” says Frederick Barrett, Ph.D., assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and a member of the school’s Center for Psychedelic and Consciousness Research.

“This will hopefully enable us to better understand why it’s an effective therapy for certain psychiatric disorders, which might help us tailor therapies to help people more.”

Because of its deep-rooted location in the brain, the claustrum has been difficult to access and study. Last year, Barrett and his colleagues at the University of Maryland, Baltimore, developed a method to detect brain activity in the claustrum using functional magnetic resonance imaging (fMRI).

In this study, the researchers used fMRI with 15 people and observed the claustrum brain region after the participants took either psilocybin or a placebo. They found that psilocybin reduced neural activity in the claustrum by 15% to 30%.

This reduced activity also appeared to be linked to the stronger subjective effects of the drug, such as emotional and mystical experiences. The team also found that psilocybin changed the way that the claustrum communicated with brain regions involved in hearing, attention, decision-making and remembering.

With the highly detailed imaging of the claustrum provided by fMRI, the researchers hope to look at this mysterious brain region in people with certain psychiatric disorders such as depression and substance use disorder.

The aim of this research would be to see what roles, if any, the claustrum plays in these conditions. The team also plans to observe the claustrum’s activity when under the influence of other psychedelics, such as salvinorin A, a hallucinogen derived from a Mexican plant.

The findings are published online in the journal NeuroImage.

Source: Johns Hopkins Medicine

https://psychcentral.com/news/2020/06/06/psilocybin-seems-to-turn-down-ego-center-in-brain/157165.html

Hollister Bioscience’s $HOLL.ca 100% Owned Subsidiary #Venom Extracts Generates Record Monthly Revenue of $3.75 million CDN in May 2020 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:18 AM on Thursday, June 11th, 2020
  • For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month
  • As compared to May 2019, Venom’s revenue increased 163%. 

VANCOUVER, BC, June 11, 2020 - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) ( FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that its 100% owned subsidiary Venom Extracts (“Venom“) generated record revenue and EBITDA for the month of May 2020. 

For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month.  As compared to May 2019, Venom’s revenue increased 163%.  The Company cautions that revenue figures have not yet been audited and are based on reports prepared by Venom management.

“We are firing on all cylinders here at Venom” shared Jake Cohen, Founder of Venom Extracts.  “Having our best month ever in terms of revenue and EBITDA speaks to the resilience of our business model in the face of these uncertain times as well as the healthy customer demand for our product line.”

“We are very excited to see these record monthly revenues. We are looking forward to replicating Venom’s business model in our California facilities and beyond.” shared Carl Saling, CEO of Hollister Biosciences Inc.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Mota Ventures $MOTA.ca Reports Monthly Revenues of Cdn$5,141,000 for Natures Exclusive, Highest in the History of the Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:19 AM on Wednesday, June 10th, 2020
  • Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019
  • 23,141 new customers during the month of May 2020

VANCOUVER, BC, CANADA / ACCESSWIRE / June 10, 2020 / Mota Ventures Corp. (CSE:MOTA) (FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) the Company’s subsidiary, Nature’s Exclusive, an eCommerce provider of CBD products to consumers in the United States, is pleased to announce an all-time monthly revenue record achieved during May 2020. Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019. Expenses totaled Cdn$4,992,000 for the month, representing a gross profit of Cdn$149,000 for May 2020.

The Company’s investment in customer acquisition continues to yield benefits with the brand acquiring 23,141 new customers during the month of May 2020. The Company’s strong ability to continue to acquire and retain new customers for its products continues to accelerate. As consumers continue to seek natural health product solutions, the Nature’s Exclusive brand is well positioned to offer consumers quality and convenience.

NATURE’S EXCLUSIVE CBD BRAND LEADING THE WAY

The Company’s Nature’s Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Nature’s Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

“I am very pleased our Nature’s Exclusive brand achieved another monthly sales record. We continued to expand in the United States, and our outlook for the second half of fiscal 2020 is very positive. We remain on track to achieve our goals for 2020 despite the recent economic turmoil,” stated Ryan Hoggan, CEO of the Company.

We encourage readers to visit www.motaventuresco.com to view our brands and sign up to our newsletter.

The Company cautions that figures for revenue, expenses and margin generated from the sale of Nature’s Exclusive products in fiscal year 2020 have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.397 for May 2020 and US$1.00:Cdn$1.3459 for May 2019.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

CLIENT FEATURE: TransCanna Holdings $TCAN.ca Developing the Largest Multi-Purpose #Cannabis Facility in California $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:08 PM on Monday, June 8th, 2020
tcan-square

(CSE: TCAN) (FSE: TH8)

Why TransCanna?

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

THE FACILITY – 196,000 Sq Ft DALY BUILDING

  • Located in Modesto, California; A key asset for TransCanna
  • 196,000 square foot building has an appraised value, prior to licensing and build out, of US $15m.
  • The indicative value once operational, post-licensing and build out is projected at US $80m.
  • Will be the largest multi-purpose cannabis facility in California.
  • Electricity Rates amongst the lowest in California

FULL DISCLOSURE: TransCanna Holdings is an advertising client of AGORA Internet Relations Corp.

Mota Ventures $MOTA.ca Signs Binding Term Sheet to Acquire E-Commerce Platform Leader Unified Funding with C$93.8 Million in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:32 AM on Saturday, June 6th, 2020

June 6, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce that it has entered into a binding term sheet (the “Term Sheet“) dated June 5, 2020 with Unified Funding LLC (“Unified“). The term sheet replaces the previous preliminary letter of intent entered into with Unified on May 21, 2020.

Ryan Hoggan, Chief Executive Officer stated “The very nature of CBD, natural health products and psychedelics unequivocally points the future of our nascent industry into digital targeting, marketing and engagement of customers who will turn to the web to learn about and acquire the right products for them. Mota has already demonstrated superior eCommerce capabilities in 2020 but this acquisition of Unified will make us a formidable presence in the space.”

Hoggan added “From a shareholder value point of view, the one thing the biggest tech companies in the world have in common – according to McKinsey – is that they are all platform-based organizations that owe much of their success to the agility with which they are able to innovate and reconfigure themselves to go after new opportunities. With this acquisition, we hope to establish a platform that will serve a growing global industry going forward.”

PLATFORM HAS FACILITATED C$364 MILLION IN TRANSACTIONS SINCE 2015, C$93.8 MILLION IN 2019

Unified is a leading eCommerce platform company established in 2015 by partners with over a decade experience in eCommerce marketing. Unified has developed a proprietary technology platform along with a CRM designed specifically for emerging, small and medium sized eCommerce businesses worldwide. To date, the platform has successfully facilitated over CDN$364,000,000 in consumer transactions, including CDN$93,800,000 in 2019 alone.

The platform generates revenue from licensing, marketing and product fulfillment fees supporting brands in the natural health products sector, including skin care, nutraceutical, essential oils and CBD. Unified brings the platform and experience needed for the Company to expand its product portfolio and brands. Integration of the platform with the Unified experienced team of professionals to run it will allow the Company to develop new products and enter new natural healthcare markets, aided significantly by Unified’s ability to closely track current trends through a global network of media partners.

Kevin Keranen, Chairman of Unified, stated “Along with a diverse team of eCommerce experts, we have built one of the most comprehensive eCommerce platforms in the natural health products sector. Our combination of technology with a full team of individuals dedicated to specific segments of the business allows us to deliver robust growth for our clients. As we look to become a part of Mota, we will be able to access the growth capital to further expand our marketing efforts and support any initiative drive by the Company in a more strategic manner.”

UNIFIED PLATFORM GOES BEYOND PRODUCT SALES

Unified provides a comprehensive suite of managed services in high-demand by its clients. These services are driven by both technology and a team of over forty United States based employees that include:

Customer Acquisition: Unified creates and executes digital marketing campaigns to acquire customers in the clients targeted demographic. By utilizing Unified’s vast marketing channels, clients are able to learn about new market trends and adapt accordingly.

Product Development: Unified is able to guide product development by utilizing intelligence generated by the millions of customer records of opt-in buyers and potential buyers. Unified has relationships with product development professionals, labs and manufacturers to create products within scope and within budget.

Supply Chain Management & Logistics: Through its partners, Unified can help manage clients supply chain to ensure on-time delivery to each customer’s doorstep and to adapt to varying levels of product demand.

Customer Service: As part of the technology platform, Unified provides real-time customer service metrics to accurately measure performance of each customer service agent, which significantly impacts the profitability of each clients business.

Profitability Analysis: Most importantly, the technology and staff at Unified are focused on profitability for each and every client. The business manages over 100 key performance indicators that have been developed through experience, which translates to higher success rates for Unified clients.

PROPOSED TRANSACTION

The Letter of Intent contemplates that the Company would acquire Unified in consideration for US$45,000,000, which will be satisfied through the issuance of common shares of the Company (the “Consideration Shares“). The Consideration Shares will be issuable at a deemed price (the “Transaction Price“) equivalent to the greater of: (i) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the entering into of a definitive agreement in respect of the acquisition, and (ii) Cdn$0.40.

In addition to the Consideration Shares, Unified will be entitled to receive a one-time bonus payment of US$15,000,000 (the “Bonus Payment“) in the event the Company achieves gross revenue in excess of US$15,000,000 from the Unified business in the twelve-month period following closing of the acquisition. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“), at the Transaction Price.

The Consideration Shares, and the Bonus Shares, will be subject to terms of a thirty-six month time-release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The shares will be released from the pooling arrangement in tranches, of which twenty percent will be released upon issuance, and the balance in six equal tranches every six months thereafter.

Completion of the proposed acquisition of Unified remains subject to a number of conditions, including, but not limited to, satisfactory completion of due diligence, negotiation of definitive documentation and the receipt of any required regulatory approvals. The acquisition cannot be completed until these conditions are satisfied and there can be no assurance that the acquisition will be completed at all.

The proposed acquisition is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding the proposed acquisition, as that information becomes available.

This press release is available for investor discussion on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on June 3, 2020 of US$1.00:Cdn$1.3504.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In German Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com